Diagnosis and Management of Allergic Rhinitis in Asthmatic Children

Figures & data

Figure 1 Overview of allergic rhinitis management.

Figure 2 General approach to allergic rhinitis by symptoms severity and recurrence.

Table 1 Characteristics of Second-Generation Oral Antihistamines

Drugs	Recommended	Pediatric Dose	Onset of Action	Sedative Effect	Food Drug Interaction
	Age		(Hours)
Bilastine	≥6 yrs	10 mg (6–11 yrs) syrup or tablet	<1	No	Yes
		20 mg (>12 yrs)
Cetirizina	≥2 yrs	2.5–5 mg (2–5 yrs)	0.7	Minimal	Yes
		5–10 mg od (6–11 yrs) syrup or tablet
Desloratadine	≥6 months	1.25 mg (1–5 yrs)	1	No	No
		2.5 mg (6–11 yrs)
Fexofenadine	≥2 yrs	30 mg tablet bid	2	No	Yes
Levocetirizine	≥6 months	5 mg (>6 yrs) od	1	No	No
		1.25 mg (2–6 yrs) bid
Loratadine	≥2 yrs	10 mg via syrup or tablet	1	No	Yes

Table 2 Characteristics of Intranasal Corticosteroids (INCS)

Drugs	Recommended	Pediatric Dose	Onset of Action	Effect on Growth
	Age
Beclometasone	≥6 yrs	1–2 puffs bid	Few days	Yes
Budesonide	≥6 yrs	1–2 puffs bid	Within 10 hours	Yes
Fluticasone furoato	≥2 yrs	1–2 puffs bid	Within 8 hour	NP
Fluticasone propionato	≥4 yrs	1–2 puffs bid	Within 12 hour	NP
Mometasone	≥2 yrs	1 puff od	Within 12 hour	No
Triamcinolone	≥2 yrs	2 puffs od/bid	Few days	NP